HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Peter Matt Thierry Carrel Duke E. Cameron Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matt, P. Articles by Dietz, H. C. Search for Related Content PubMed Articles by Matt, P. Articles by Dietz, H. C.

J Thorac Cardiovasc Surg 2008;135:389-394
© 2008 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Recent advances in understanding Marfan syndrome: Should we now treat surgical patients with losartan?

^a Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Md
^b Division of Cardiac Surgery, Basel, Switzerland
^c Division of Cardiac, Johns Hopkins Medical Institutions, Baltimore, Md
^d Johns Hopkins Proteomics Center, Baltimore, Md.

Received for publication August 3, 2007; accepted for publication August 30, 2007.

^_* Address for reprints: Peter Matt, MD, Johns Hopkins Medicine, 5200 Eastern Avenue, 601 Mason F. Lord Bldg, Baltimore, MD 21224. (Email: pmatt{at}uhbs.ch).

Objective: Marfan syndrome is a systemic connective tissue disorder caused by mutations in the fibrillin-1 gene. It was originally believed that Marfan syndrome results exclusively from the production of abnormal fibrillin-1 that leads to structurally weaker connective tissue when incorporated into the extracellular matrix. This effect seemed to explain many of the clinical features of Marfan syndrome, including aortic root dilatation and acute aortic dissection, which represent the main causes of morbidity and mortality in Marfan syndrome.

Methods: Recent molecular studies, most based on genetically defined mouse models of Marfan syndrome, have challenged this paradigm. These studies established the critical contribution of fibrillin-1 haploinsufficiency and dysregulated transforming growth factor-beta signaling to disease progression.

Results: It seems that many manifestations of Marfan syndrome are less related to a primary structural deficiency of the tissues than to altered morphogenetic and homeostatic programs that are induced by altered transforming growth factor-beta signaling. Most important, transforming growth factor-beta antagonism, through transforming growth factor-beta neutralizing antibodies or losartan (an angiotensin II type 1 receptor antagonist), has been shown to prevent and possibly reverse aortic root dilatation, mitral valve prolapse, lung disease, and skeletal muscle dysfunction in a mouse model of Marfan syndrome.

Conclusion: There are indicators that losartan, a drug widely used to treat arterial hypertension in humans, offers the first potential for primary prevention of clinical manifestations in Marfan syndrome.

This article has been cited by other articles:

				C. Pilop, F. Aregger, R. C. Gorman, R. Brunisholz, B. Gerrits, T. Schaffner, J. H. Gorman III, G. Matyas, T. Carrel, and B. M. Frey Proteomic Analysis in Aortic Media of Patients With Marfan Syndrome Reveals Increased Activity of Calpain 2 in Aortic Aneurysms Circulation, September 15, 2009; 120(11): 983 - 991. [Abstract] [Full Text] [PDF]

				P. Matt, F. Schoenhoff, J. Habashi, T. Holm, C. Van Erp, D. Loch, O. D. Carlson, B. F. Griswold, Q. Fu, J. De Backer, et al. Circulating Transforming Growth Factor-{beta} in Marfan Syndrome Circulation, August 11, 2009; 120(6): 526 - 532. [Abstract] [Full Text] [PDF]

				M. D. Everitt, N. Pinto, J. A. Hawkins, M. B. Mitchell, P. C. Kouretas, and A. T. Yetman Cardiovascular surgery in children with Marfan syndrome or Loeys-Dietz syndrome. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1327 - 1333. [Abstract] [Full Text] [PDF]

				P. Matt and F. Eckstein eComment: Stabilizing aortic tissue after aortic root surgery in Marfan syndrome Interactive CardioVascular and Thoracic Surgery, December 1, 2008; 7(6): 1166 - 1166. [Full Text] [PDF]

				A. W.Y. Chung, H. H. C. Yang, M. W. Radomski, and C. van Breemen Long-Term Doxycycline Is More Effective Than Atenolol to Prevent Thoracic Aortic Aneurysm in Marfan Syndrome Through the Inhibition of Matrix Metalloproteinase-2 and -9 Circ. Res., April 25, 2008; 102(8): e73 - e85. [Abstract] [Full Text] [PDF]